Ga-68-PSMA PET/CT预测临床低危前列腺癌根治术后升级
回顾性分析75例活检ISUP分级组1且行根治性前列腺切除术的患者,评估临床病理变量、mpMRI及Ga-68-PSMA PET/CT对病理升级的预测价值。根治术后病理升级率为49.3%。多因素分析显示PI-RADS 4-5病变(OR 3.354,95%CI 1.124-10.007,p=0.030)和SUVmax≥4.6(OR 6.113,95%CI 1.893-19.875,p=0.002)是升级的预测因子。
要点
- 活检ISUP GG1患者根治术后病理升级率高达49.3%,需重视风险重分类。
- mpMRI PI-RADS 4-5病变和PSMA PET/CT SUVmax≥4.6是独立预测因子。
- SUVmax预测升级的ROC曲线截断值为4.6 g/mL。
关键影像表现/征象
- 未升级组PI-RADS 3、4、5评分分别占71.1%、18.4%、2.6%,升级组分别占51.4%、18.9%、29.7%(p=0.002)。
- 升级组mpMRI指数病灶平均直径更高(p=0.007)。
- 未升级组SUVmax为4.65,升级组为7(p=0.003)。
诊断标准与关键数值
- 活检ISUP GG1患者根治术后ISUP GG升级检出率为49.3%。
- SUVmax预测升级的ROC曲线截断值为4.6 g/mL。
- 多因素分析中PI-RADS 4-5病变OR为3.354(95%CI 1.124-10.007,p=0.030),SUVmax≥4.6的OR为6.113(95%CI 1.893-19.875,p=0.002)。
临床应用与阅片要点
- 对活检ISUP GG1患者,若mpMRI显示PI-RADS 4-5病变或PSMA PET/CT SUVmax≥4.6,应提示高风险重分类可能,建议结合临床调整管理策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the role of clinical and pathological variables, multiparametric magnetic resonance imaging (mpMRI), and Ga-68-PSMA PET/CT in prediction upgrading in patients who underwent radical prostatectomy (RP) for clinically insignificant prostate cancer (ciPCa).
METHODS: Patients with The International Society of Urological Pathology (ISUP) grade group(GG) 1 by biopsy (bISUP GG 1) who underwent Ga-68-PSMA PET were reviewed. 38 who did not upgrade after RP were defined as group 1, and 37 who were upgraded after RP were defined as group 2.
RESULTS: In patients with bISUP GG 1, the upgrade detection rate of the ISUP GG on RP material was 49.3%. PI-RADS 3, 4, and 5 scores were 71.1%, 18.4%, and 2.6% in group 1, respectively, whereas 51.4%, 18.9%, and 29.7% in group 2, respectively (p = 0.002). Mean index lesion diameter on mpMRI (p = 0.007) were found to be higher in patients who upgraded. The SUVmax detected on Ga-68-PSMA PET/CT was 4.65 in group 1 and 7 in group 2 (p = 0.003). ROC curve analysis provided a cut-off value of 4.6 g/mL for the SUVmax that would predict upgrading. PI-RADS 4-5 lesions on mpMRI (OR: 3.354, 95% CI: 1.124-10.007, p = 0.030) and SUVmax ≥ 4.6 on PSMA PET/CT (OR: 6.113, 95%CI: 1.893-19.875, p = 0.002) were found to be predictors for upgrading in multivariate analysis.
CONCLUSIONS: Ga-68-PSMA PET/CT was found to be a potentially useful imaging biomarker for predicting pathological upgrading from combined systematic biopsy and mpMRI- targeted biopsy to RP.
ADVANCES IN KNOWLEDGE: For patients with ciPCa, there is a high likelihood of risk reclassification if they have PI-RADS 4-5 score and SUVmax higher than 4.6 on Ga-68-PSMA PET/CT.
引用
- Özbilen MH, Karaca E, Sağmak B, et al. Prediction of upgrading in clinically insignificant prostate cancer patients undergoing radical prostatectomy: the value of Ga-68-PSMA PET/CT. Br J Radiol. 2026. PMID: 42001221. doi:10.1093/bjr/tqag085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。